Apnimed will present new research, including the prevalence of obesity in obstructive sleep apnea, at SLEEP 2024. 

Summary: Apnimed Inc, a clinical-stage pharmaceutical company, will present five key studies and host a symposium at the SLEEP 2024 annual meeting, with highlights including an epidemiologic study showing that most OSA patients are not obese. Additional presentations will cover the phase 3 SynAIRgy study design for AD109, Apnimed’s oral nighttime OSA drug, and data from the VicTor phase 2 crossover study of AD817. CEO Larry Miller underscores the potential of AD109 to address the neuromuscular root cause of OSA across diverse patient profiles.

Key Takeaways: 

  • Apnimed will present five studies and host a symposium at the SLEEP 2024 annual meeting.
  • An epidemiologic study by Apnimed reveals that the majority of obstructive sleep apnea patients are not obese.
  • Apnimed will discuss the design and rationale of the SynAIRgy phase 3 trial for AD109, an investigational oral drug targeting neuromuscular dysfunction in OSA.

Apnimed Inc, a clinical-stage pharmaceutical company developing oral therapies for the treatment of obstructive sleep apnea (OSA) and other sleep disorders, announced a series of five data presentations and a dinner symposium at SLEEP 2024.

Presentations include an epidemiologic study of the prevalence of obesity in OSA, which demonstrates that the majority of people with OSA are not obese, underscoring the need for new OSA treatments that go beyond weight loss to address the neuromuscular root cause of the disease. 

Other presentations related to Apnimed’s pipeline of potential OSA treatments include both an oral and a poster discussion concerning the study design and rationale of SynAIRgy, the second phase 3 registrational study for AD109, and data from the VicTor study, a phase 2 crossover study that evaluated an oral combination drug related to Apnimed’s pipeline development candidate AD817.

“Apnimed is making significant contributions toward understanding the characteristics of people with OSA and the impact symptoms of OSA have on those who are not being treated. The data being presented at SLEEP 2024 reaffirm that this market has significant unmet needs,” says Larry Miller, MD, CEO of Apnimed, in a release. “AD109, our novel oral nighttime drug for OSA, currently in phase 3 clinical development, has the potential to help patients across a broad spectrum of OSA severity and body mass index by addressing the neuromuscular root cause of OSA. Because there are no FDA approved products that specifically address the neuromuscular dysfunction of OSA, the door is open for an oral therapy that can meet the needs of a broad range of OSA patients.”

Apnimed SLEEP 2024 Presentation Details:

POSTER:P-09, #147Prevalence of Obesity in Obstructive Sleep Apnea within a Large Community-based Cohort of Middled-aged/Older Adults
Time: Monday, June 3, 10-10:45 AM CT
Location:George R. Brown Convention Center, Hall A3
Presenter:Neda Esmaeili, PhD, Brigham and Women’s Hospital
POSTER:P-08, #133Fatigue Negatively Impacts the Lives of Individuals Living with OSA: A Closer Look with Patient Reported Outcomes (PRO) Measures
Time:Monday, June 3, 10-10:45 AM CT
Location:George R. Brown Convention Center, Hall A3
Presenter:Helene Emsellem, MD, Director, The Center for Sleep & Wake Disorders & Sleep Health Institute
Event:Shining a Light on Living with Sleep Apnea
Sneak Preview:“Out of Breath,” an independent film about living with OSA  followed by a panel discussion with the film’s director and stars
Time:Tuesday, June 4, 6:15-8:30PM CT
Location:Marriott Marquis, Houston, Salon A-B
Register:https://bit.ly/3y2gbqe
ORAL:O-26Aroxybutynin and Atomoxetine for the Treatment of OSA: Rationale and Design of theSynAIRgy Phase 3 RCT
Session:Updates on Non-PAP Therapy for Sleep-Related Breathing Disorders
Time: Wednesday, June 5, 2:15-2:30PM CT
Location:George R. Brown Convention Center, Room 362
Presenter:Patrick Strollo, Jr., MD, Professor of Medicine and Clinical and Translational Science,Vice Chair of Medicine for Veterans Affairs, University of Pittsburgh School of Medicine
POSTER:P-41, #274Aroxybutynin and Atomoxetine for the Treatment of OSA: Rationale and Design of the SynAIRgy Phase 3 RCT
Time: Wednesday, June 5, 11-11:45 AM CT
Location: George R. Brown Convention Center, Hall A3
Presenter:Patrick Strollo, Jr., MD, Professor of Medicine and Clinical and Translational Science,Vice Chair of Medicine for Veterans Affairs, University of Pittsburgh School of Medicine
ORAL:O-26The Effect of Viloxazine and Trazodone in Obstructive Sleep Apnea Patients: A Randomized, Placebo-controlled, Crossover Study
Session:Updates on Non-PAP Therapy for Sleep-Related Breathing Disorders
Time: Wednesday, June 5, 2:30-2:45PM CT
Location:George R. Brown Convention Center, Room 362
Presenter:Atqiya Aishah, PhD, Brigham and Women’s Hospital
  

Photo 124538395 © Andrey Popov | Dreamstime.com